Grupo de Investigación en Fisiopatología Cardiovascular
CTS237
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (16)
2024
2022
2021
2019
-
Comparison of seven prognostic tools to identify low-risk pulmonary embolism in patients aged <50 years
Scientific Reports, Vol. 9, Núm. 1
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
-
Low performance of ultrasound surveillance for the diagnosis of hepatocellular carcinoma in HIV-infected patients
AIDS, Vol. 33, Núm. 2, pp. 269-278
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Characteristics, treatment patterns and outcomes of patients presenting with venous thromboembolic events after knee arthroscopy in the RIETE Registry
Journal of Thrombosis and Thrombolysis, Vol. 46, Núm. 4, pp. 551-558
-
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients
AIDS, Vol. 32, Núm. 11, pp. 1423-1430
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
2015
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
2014
2009
-
Prevalencia de enfermedad arterial periférica asintomática en pacientes con ictus isquémico no cardioembólico
Neurologia, Vol. 24, Núm. 6, pp. 366-372
2005
-
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma
Cancer Chemotherapy and Pharmacology, Vol. 55, Núm. 2, pp. 197-202
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81